

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number
WO 2005/082406 A1

(51) International Patent Classification⁷: **A61K 38/38**

(21) International Application Number:
PCT/GB2005/000685

(22) International Filing Date: 24 February 2005 (24.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0404369.1 26 February 2004 (26.02.2004) GB
0404339.4 26 February 2004 (26.02.2004) GB
0404358.4 26 February 2004 (26.02.2004) GB

(71) Applicant (for all designated States except US): **HAM-
LET PHARMA AB** [SE/SE]; Lilla Fiskaregatan 10, S-222
22 Lund (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SVANBORG, Catha-
rina** [SE/SE]; Lund University, Department of Medical Mi-
crobiology, Section of Clinical Immunology, Sölvegatan
23, S-223 62 Lund (SE).

(74) Agent: **GREAVES, Carol, Pauline**; Greaves Brewster
LLP, Indigo House, Cheddar Business Park, Wedmore
Road, Cheddar, BS27 3EB (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: LACTALBUMIN FOR INHIBITING ANGIOGENESIS

(57) Abstract: The use of a biologically active complex of α -lactalbumin, selected from HAMLET (human α -lactalbumin made lethal to tumour cells) or a biologically active modification thereof, or a biologically active fragment of either of these, in the prepa-
ration of a medicament for use in the treatments of proliferative disease and in particular of mucosal cancers such as bladder cancer
or malignant melanoma, as well as tumours of internal organs such as glioblastoma, as well as in the inhibition of angiogenesis.



WO 2005/082406 A1